FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308462847> ?p ?o ?g. }

• W4308462847 abstract "ABSTRACT Persistent inflammation including type-one interferon (IFN-I) can cause immunosuppression. We show that delayed administration of the JAK1 inhibitor itacitinib after anti-PD1 improves immune function and anti-tumor response in mice, and results in high response rates (67%) in a phase-2 clinical trial for metastatic non-small cell lung cancer with tumor PDL1≥50%. In contrast to patients with low inflammation who responded to anti-PD1, patients with elevated inflammation had poor immune and tumor responses to anti-PD1 that improved after adding itacitinib. Itacitinib promoted features of CD8 T cell plasticity and therapeutic responses of exhausted and effector-memory clonotypes. Patients with persistent IFN-I signaling refractory to itacitinib showed progressive CD8 T cell terminal differentiation and progressive disease. Thus, JAK inhibition may improve anti-PD1 efficacy by pivoting T cell differentiation dynamics." @default.
• W4308462847 created "2022-11-12" @default.
• W4308462847 creator A5002118601 @default.
• W4308462847 creator A5004260080 @default.
• W4308462847 creator A5007235827 @default.
• W4308462847 creator A5011095026 @default.
• W4308462847 creator A5018068596 @default.
• W4308462847 creator A5022335574 @default.
• W4308462847 creator A5022346171 @default.
• W4308462847 creator A5033986209 @default.
• W4308462847 creator A5037836890 @default.
• W4308462847 creator A5042972592 @default.
• W4308462847 creator A5051601925 @default.
• W4308462847 creator A5054642059 @default.
• W4308462847 creator A5059929721 @default.
• W4308462847 creator A5066745294 @default.
• W4308462847 creator A5071859611 @default.
• W4308462847 creator A5087521324 @default.
• W4308462847 creator A5090256464 @default.
• W4308462847 date "2022-11-07" @default.
• W4308462847 modified "2023-10-17" @default.
• W4308462847 title "Durable Response and Improved CD8 T Cell Plasticity in Lung Cancer Patients After PD1 Blockade and JAK Inhibition" @default.
• W4308462847 cites W2024556668 @default.
• W4308462847 cites W2032166347 @default.
• W4308462847 cites W2038576929 @default.
• W4308462847 cites W2049868800 @default.
• W4308462847 cites W2101910308 @default.
• W4308462847 cites W2314851760 @default.
• W4308462847 cites W2465860350 @default.
• W4308462847 cites W2513922839 @default.
• W4308462847 cites W2527905628 @default.
• W4308462847 cites W2558219863 @default.
• W4308462847 cites W2561322596 @default.
• W4308462847 cites W2605630275 @default.
• W4308462847 cites W2889555301 @default.
• W4308462847 cites W2902856530 @default.
• W4308462847 cites W2903493397 @default.
• W4308462847 cites W2925446385 @default.
• W4308462847 cites W2968188498 @default.
• W4308462847 cites W2969539132 @default.
• W4308462847 cites W2991888163 @default.
• W4308462847 cites W2994331021 @default.
• W4308462847 cites W3020888809 @default.
• W4308462847 cites W3124696121 @default.
• W4308462847 cites W4200468913 @default.
• W4308462847 cites W4220839040 @default.
• W4308462847 cites W4292229922 @default.
• W4308462847 cites W4297088172 @default.
• W4308462847 cites W4307040885 @default.
• W4308462847 cites W4307890047 @default.
• W4308462847 cites W4308661885 @default.
• W4308462847 doi "https://doi.org/10.1101/2022.11.05.22281973" @default.
• W4308462847 hasPublicationYear "2022" @default.
• W4308462847 type Work @default.
• W4308462847 citedByCount "3" @default.
• W4308462847 countsByYear W43084628472023 @default.
• W4308462847 crossrefType "posted-content" @default.
• W4308462847 hasAuthorship W4308462847A5002118601 @default.
• W4308462847 hasAuthorship W4308462847A5004260080 @default.
• W4308462847 hasAuthorship W4308462847A5007235827 @default.
• W4308462847 hasAuthorship W4308462847A5011095026 @default.
• W4308462847 hasAuthorship W4308462847A5018068596 @default.
• W4308462847 hasAuthorship W4308462847A5022335574 @default.
• W4308462847 hasAuthorship W4308462847A5022346171 @default.
• W4308462847 hasAuthorship W4308462847A5033986209 @default.
• W4308462847 hasAuthorship W4308462847A5037836890 @default.
• W4308462847 hasAuthorship W4308462847A5042972592 @default.
• W4308462847 hasAuthorship W4308462847A5051601925 @default.
• W4308462847 hasAuthorship W4308462847A5054642059 @default.
• W4308462847 hasAuthorship W4308462847A5059929721 @default.
• W4308462847 hasAuthorship W4308462847A5066745294 @default.
• W4308462847 hasAuthorship W4308462847A5071859611 @default.
• W4308462847 hasAuthorship W4308462847A5087521324 @default.
• W4308462847 hasAuthorship W4308462847A5090256464 @default.
• W4308462847 hasBestOaLocation W43084628471 @default.
• W4308462847 hasConcept C126322002 @default.
• W4308462847 hasConcept C154317977 @default.
• W4308462847 hasConcept C167672396 @default.
• W4308462847 hasConcept C170493617 @default.
• W4308462847 hasConcept C202751555 @default.
• W4308462847 hasConcept C203014093 @default.
• W4308462847 hasConcept C2776090121 @default.
• W4308462847 hasConcept C2776256026 @default.
• W4308462847 hasConcept C2776914184 @default.
• W4308462847 hasConcept C2777701055 @default.
• W4308462847 hasConcept C2778468042 @default.
• W4308462847 hasConcept C2780252810 @default.
• W4308462847 hasConcept C2780851360 @default.
• W4308462847 hasConcept C502942594 @default.
• W4308462847 hasConcept C55493867 @default.
• W4308462847 hasConcept C71924100 @default.
• W4308462847 hasConcept C86803240 @default.
• W4308462847 hasConcept C8891405 @default.
• W4308462847 hasConceptScore W4308462847C126322002 @default.
• W4308462847 hasConceptScore W4308462847C154317977 @default.
• W4308462847 hasConceptScore W4308462847C167672396 @default.
• W4308462847 hasConceptScore W4308462847C170493617 @default.
• W4308462847 hasConceptScore W4308462847C202751555 @default.
• W4308462847 hasConceptScore W4308462847C203014093 @default.
• W4308462847 hasConceptScore W4308462847C2776090121 @default.

• next